Filing Details
- Accession Number:
- 0001447362-24-000129
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-08-13 18:13:49
- Reporting Period:
- 2024-08-07
- Accepted Time:
- 2024-08-13 18:13:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1447362 | Castle Biosciences Inc | CSTL | Services-Medical Laboratories (8071) | 770701774 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1782815 | Frank Stokes | C/O Castle Biosciences, Inc. 505 S. Friendswood Drive, Suite 401 Friendswood TX 77546 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-08-07 | 4,600 | $25.20 | 36,223 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-08-07 | 5,400 | $26.13 | 30,823 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on May 06, 2024.
- This transaction was executed in multiple trades at prices ranging from $24.840 to $25.535, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- Includes 1,272 shares acquired on February 29, 2024, under the Issuer's employee stock purchase plan.
- This transaction was executed in multiple trades at prices ranging from $25.845 to $26.405, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Billionaire Hedge Funds
